Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 14Active not recruiting 6Recruiting 4Withdrawn 2Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 44Liver Neoplasms 4Cholangiocarcinoma 3Advanced Biliary Tract Cancer 3Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Liver Cirrhosis 1Klatskin Tumor 1Hepatoblastoma 1HER2-negative Advanced Gastric Cancer 1Gastric Cancer Metastatic to Liver 1Gallbladder Neoplasms 1First-line Treatment 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Tumor 1Biliary Tract Neoplasms Immunotherapy 1Advanced Primary Liver Cancer 1

Interventions

Exercise 18Drug Therapy 17pembrolizumab 12Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Dexamethasone 9Paclitaxel 8Standard of Care 7Oxaliplatin 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Control Groups 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neoplasms × lenvatinib × Clear all
NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

National Health Research Institutes, Taiwan

Phase 1 Unknown
12 enrolled
Tumor-Agnostic

Neoplasms

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown
15 enrolled
Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡